NHS Dudley Health Economy Medicines Formulary
Home > 8 Malignant disease and immunosuppression > 8.2 Drugs affecting the immune response > 8.2.4 Other immunomodulating drugs > Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases - NICE TAG TA376

Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases - NICE TAG TA376

1.1 Radium‑223 dichloride is recommended as an option for treating adults with hormone‑relapsed prostate cancer, symptomatic bone metastases and no known visceral metastases, only if:

  • they have had treatment with docetaxel, and

  • the company provides radium‑223 dichloride with the discount agreed in the patient access scheme.

1.2 People whose treatment with radium‑223 dichloride is not recommended in this NICE guidance, but was started within the NHS before this guidance was published, should be able to continue treatment until they and their NHS clinician consider it appropriate to stop.

 

https://www.nice.org.uk/guidance/ta376 

Site by Devopa
© Copyright 2019 NHS. All rights reserved.